Skip to content
ChickenStockChickenStock
ResearchIPSC
Century Therapeutics logo

Century Therapeutics (IPSC) stock

NASDAQ

$1.36-16.77%(-0.28)

As of the Nov 17, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-2.48x

Net loss — not comparable

P/B

1.18x

P/S

2.28x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Operating income increased from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 12, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

10 SEC filings
  • Pfeiffenberger BrentPresident and CEO · Nov 13, 2026Shares withheld for taxes31,172 shares · $51K
    Avg. price $1.653,602,667 shares held after
  • Carr DouglasSVP Finance & Operations · Nov 3, 2026Open-market sale266 shares · $404
    Avg. price $1.519502,641 shares held after
  • Russotti GregorySee Remarks · Sep 14, 2026Open-market sale2,587 shares · $5K
    Avg. price $1.93509,198 shares held after
  • Carr DouglasSVP Finance & Operations · Sep 14, 2026Open-market sale1,658 shares · $3K
    Avg. price $1.93502,907 shares held after
  • Pfeiffenberger BrentPresident and CEO · Sep 11, 2026Shares withheld for taxes13,850 shares · $27K
    Avg. price $1.943,633,839 shares held after
  • Russotti GregorySee Remarks · Sep 8, 2026Open-market sale534 shares · $1K
    Avg. price $2.05511,785 shares held after
  • Carr DouglasSVP Finance & Operations · Sep 8, 2026Open-market sale254 shares · $521
    Avg. price $2.05504,565 shares held after
  • Pfeiffenberger BrentPresident and CEO · Sep 4, 2026Shares withheld for taxes463 shares · $977
    Avg. price $2.113,633,839 shares held after
  • Pfeiffenberger BrentPresident and CEO · Aug 14, 2026Shares withheld for taxes31,172 shares · $60K
    Avg. price $1.923,634,302 shares held after
  • Carr DouglasSVP Finance & Operations · Aug 3, 2026Open-market sale275 shares · $544
    Avg. price $1.977504,819 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Century Therapeutics (IPSC) stock information

NASDAQ

Century Therapeutics (IPSC) is listed on NASDAQ. Its market capitalization is about $248M. On trailing-twelve-month earnings the P/E ratio is -2.48, and the P/B ratio is 1.18. Return on equity is -47.6%. These figures are computed in-house from official filings and are reference information only.

Century Therapeutics — frequently asked questions

What is the P/E ratio of Century Therapeutics (IPSC)?
On a trailing-twelve-month basis, IPSC trades at a P/E ratio of -2.48. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Century Therapeutics?
IPSC has a market capitalization of about $248M. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.